This post summarizes editorialized reporting based on research by A Midwestern Doctor. It is commentary and historical overview—not medical advice.

A cheap solvent with unusual powers

DMSO is mostly produced as a byproduct of the wood-pulp and paper industry, which keeps it inexpensive and widely available. In the early 1960s, Crown Zellerbach chemist Robert Herschler noticed it could carry dyes through skin. Surgeon Stanley Jacob, searching for better ways to preserve transplant organs, began testing it and quickly reported rapid systemic absorption—famously tasting iodine after applying an iodine–DMSO mix to the skin.

Early clinical enthusiasm followed: burns, sprains, musculoskeletal pain, and other hard-to-treat complaints. Jacob and others poured careers into the compound. Pharmaceutical interest briefly surged. Then regulation reshaped the story.

Why a “too versatile” drug alarmed regulators

According to this Vigilant Fox piece (drawing on Midwestern Doctor’s history), DMSO collided with an FDA newly empowered after the thalidomide disaster and the 1962 expansion of drug law. A substance used alone and in combinations, for many indications, did not fit a narrow approval pipeline. In late 1965, after preliminary high-dose dog data suggested eye-lens changes, U.S. testing was sharply restricted. Critics note those ocular effects were not confirmed in large human experience or in monkeys, and a widely cited death was disputed as multifactorial—yet the chill on research was real.

Public trust flipped

Because industrial DMSO remained legal to buy, patients did not wait for prescriptions. A 1980 60 Minutes segment and congressional hearings amplified the sense that institutions were stonewalling. A 1985 diffusion-of-innovation study of DMSO users found a diverse group treating arthritis, injuries, burns, psoriasis, headaches, and more. Many first heard about it from television or friends; fewer trusted physicians for verification. For some, official disapproval became a reason to believe the therapy was effective—an inversion of usual medical trust.

Never fully gone

The U.S. never erased DMSO from medicine. It stayed approved for interstitial cystitis, ubiquitous as a lab solvent and cryopreservative, and used as a vehicle for other drugs. Outside the U.S., the Soviet Union approved “Dimexide” in 1971, and research continued in Russia, Ukraine, China, Latin America, and Germany. Suppression, the article argues, did not kill demand—it moved demand into hobby shops, peer networks, and foreign literature.

The modern lesson

The Fox framing is less “DMSO cures everything” and more “how institutions lose the benefit of the doubt.” When people feel ignored while dealing with chronic pain, they share anecdotes faster than journals can respond. That pattern is appearing again online. Responsible curiosity means separating marketing hype from documented effects, insisting on clean product and skin hygiene (because DMSO carries contaminants inward), and keeping licensed clinicians in the loop.

Source

Original article: How DMSO Became One of the Strangest Stories in Medicine — The Vigilant Fox (May 2, 2026), based on reporting by A Midwestern Doctor.